OPC-3.....碧蘿芷 @ 芊芊說說

碧蘿芷®比處方藥物阻止血糖吸收的能力高190倍

Pycnogenol® Delays Glucose Absorption 190 Times More Potently than Prescription Medication

新的研究實驗說明了碧蘿芷®是如何降低糖尿病人血糖水平的。
New Study discovers how Pycnogenol® lowers Blood Glucose Levels in Type II Diabetes

在即將刊登於新一期的糖尿病研究通訊和臨床實踐雜誌上的一篇有關法國沿海松樹皮提取物碧蘿芷®的實驗文章中寫道，與處方藥物相比，碧蘿芷®可以將患者餐後血糖峰值來臨的時間推遲190倍，實驗假設病人的血糖峰值出現在餐後。實驗表明，碧蘿芷®在抑制碳水化合物吸收方面的效果要大大強于人工合成的處方藥物阿爾法-葡萄糖苷酶抑制劑，如Precose。
A new study to be published in an upcoming edition of the journal of Diabetes Research and Clinical Practice reveals that French maritime pine tree extract known as Pycnogenol® (pic-noj-en-all) delays the uptake of glucose from a meal 190 times more than prescription medications, preventing the typical high glucose peak in the blood stream after a meal. The study revealed the pine bark is more potent for suppressing carbohydrate absorption in diabetes than synthetic prescription alpha-glucosidase inhibitors such as Precose.

“患II型糖尿病的患者人數越來越多，”此項實驗的實驗帶頭人Petra Hogger博士說。“這項實驗對於患有II型糖尿病的患者來說很有意義，因為這項實驗證明了碧蘿芷®的降血糖效果要強於Precose等處方藥物，同時，這也很好的佐證了其他的有關碧蘿芷®對糖尿病治療功效的實驗結果。”
"Diabetes mellitus type II is a serious disease with rising prevalence," said Dr. Petra Högger, a lead researcher of this study. "This study is crucial for those suffering with the disease because it affirms that Pycnogenol® is more effective than prescription medication Precose® and supports the abundance of other research done on Pycnogenol® and diabetes."

這項實驗是在德國的烏茲堡完成的，Högger博士研究了碧蘿芷®與阿爾法-葡萄糖苷酶的相互作用情況，阿爾法-葡萄糖苷酶的作用是分解食物中的碳水化合物。結果表明，碧蘿芷®抑制阿爾法-葡萄糖苷酶的作用比人工抑制劑acarbose強190倍。Acarbose是一種常用的用於治療II型糖尿病的處方藥物，在歐洲銷售的名字叫做Glucobay，在美國銷售的名稱為Precose。
The study was conducted at the University of Wurzburg Germany. Dr. Högger investigated the interaction of Pycnogenol® with the enzyme alpha-glucosidase, which breaks down carbohydrates in a meal. Results revealed Pycnogenol® is 190 times more potent for inhibition of alpha-glucosidase than the synthetic inhibitor acarbose, a common prescription medication for treatment of type II diabetes (sold in Europe under the name Glucobay® and the United States under the name Precose®).

碧蘿芷®可以抑制腸道內的負責如澱粉和白糖等複合碳水化合物的消化的酶（阿爾法-葡萄糖苷酶）的活動能力。阿爾法-葡萄糖苷酶可以將碳水化合物分解成葡萄糖，葡萄糖會被吸收到血液中去。
Pycnogenol® was shown to inhibit the intestinal enzymes (alpha-glucosidase) involved in the digestion of complex carbohydrates such as starch and normal table sugar. The alpha-glucosidase breaks down carbohydrates into glucose molecules which are then absorbed into the blood stream.

“碧蘿芷®中所含有的高濃度的前花青素（生物類黃酮）是發揮這一奇特作用的主要成分，”Högger博士說。Högger博士介紹道，較大分子的前花青素分子在抑制阿爾法-葡萄糖苷酶活性方面顯得更為活躍，這就解釋了碧蘿芷®發揮作用的原因。“碳水化合物進入血液後在很長的一段時間內保持穩定，這就增強了每餐的效果，同時也推遲了饑餓感的出現。”
"The high concentration of procyanidins (flavonoids) found in Pycnogenol® is responsible for demonstrating these excellent results," said Högger. According to Högger, the large procyanidin molecules were found to be particularly active for inhibiting the activity of alpha-glucosidase, thus demonstrating such notable results. "The carbohydrates enter the blood stream steadily over prolonged periods of time, which makes meals last longer and prolong satiety."

在2004年進行的兩項相對獨立的實驗中，實驗都證實了碧蘿芷®對於降低II型糖尿病患者血糖水平的功效。發表在2004年3月刊糖尿病保健雜誌上的文章中寫道，II型糖尿病患者服用碧蘿芷®之後，其餐後血糖水平和空腹血糖水平均得到了降低。另外一篇發表在10月刊的生命科學雜誌上的文章則記載了碧蘿芷®在治療糖尿病藥物acarbose和metformin改善效果基礎上，進一步降低了病人的血糖水平。
In two separate studies conducted in 2004, Pycnogenol® was found to significantly lower blood sugar levels in type II diabetes patients. A study published in the March 2004 edition of Diabetes Care revealed that patients who supplemented with Pycnogenol® experienced lower blood sugar after meals and lower fasting blood sugar. Another study published in the October edition of Life Sciences revealed a significantly further lowered blood glucose level in patients who supplemented with Pycnogenol® while continuing their anti-diabetic medication with acarbose and metformin.

這一研究成果開闢了碧蘿芷®應用在治療糖尿病、新陳代謝紊亂和肥胖症領域的新道路。“在美國，有7%的人口被確診為糖尿病，不到五個人中就有一個人患有新陳代謝紊亂疾病，6千萬美國成年人都屬於肥胖人群，因此找到一種能夠改善這些狀況、提高生活治療的天然、安全的產品非常有意義，”Högger說。
This study opens new a venues for product development of Pycnogenol® in the field of diabetes, metabolic syndrome and obesity. “With seven percent of Americans diagnosed with diabetes, more than one in five people afflicted with metabolic syndrome, and 60 million U.S. adults considered obese, finding natural and safe options for managing these conditions and improving quality of life is a priority,” said Högger.